FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2318121605> ?p ?o ?g. }

• W2318121605 endingPage "1869" @default.
• W2318121605 startingPage "1859" @default.
• W2318121605 abstract "There are no current pharmacological therapies for the prevention or treatment of acute respiratory distress syndrome. Early dysregulated inflammation likely plays a role in acute respiratory distress syndrome development and possibly acute respiratory distress syndrome outcomes. p38 mitogen-activated protein kinase is central to the regulation of multiple inflammatory mediators implicated in acute organ dysfunction and is the target for a novel class of cytokine-suppressive anti-inflammatory drugs. In preclinical models, p38 inhibitors reduce lung injury following pancreatitis and burn injury.We conducted a phase IIa, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and tolerability of dilmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in patients at risk for developing acute respiratory distress syndrome admitted with an Injury Severity Score more than 16, excluding head trauma. Enrolled patients received 4- or 24-hour IV dilmapimod infusions at different doses or placebo, daily for 3 days, in four separate cohorts.Multicenter randomized clinical trial of large, academic trauma centers.Seventy-seven patients were enrolled. Although adverse events were common in this critically ill population, dilmapimod was well tolerated, with no clinically relevant safety findings. Pharmacokinetic models indicated that the higher dose of 10 mg given as continuous infusion over 24 hours had the most favorable plasma concentration profile. Likewise, measures of soluble inflammatory markers including interleukin-6, C-reactive peptide, interleukin-8, and soluble tumor necrosis factor receptor 1 were most different between this dosing arm and placebo. Although the study was not specifically designed with acute respiratory distress syndrome as an outcome, the number of patients who developed acute respiratory distress syndrome was small (2/77).The novel p38 mitogen-activated protein kinase inhibitor dilmapimod appears well tolerated and may merit further evaluation for prevention of acute respiratory distress syndrome and other organ injury in larger clinical trials. Furthermore, results of this early-phase trial may aid in design of future studies aimed at prevention of acute respiratory distress syndrome and other organ injury." @default.
• W2318121605 created "2016-06-24" @default.
• W2318121605 creator A5012242776 @default.
• W2318121605 creator A5012908451 @default.
• W2318121605 creator A5019832166 @default.
• W2318121605 creator A5029172499 @default.
• W2318121605 creator A5042741758 @default.
• W2318121605 creator A5046686843 @default.
• W2318121605 creator A5055992770 @default.
• W2318121605 creator A5064895812 @default.
• W2318121605 creator A5070182407 @default.
• W2318121605 creator A5074806717 @default.
• W2318121605 creator A5077430660 @default.
• W2318121605 creator A5085685364 @default.
• W2318121605 date "2015-09-01" @default.
• W2318121605 modified "2023-10-06" @default.
• W2318121605 title "A Randomized Dose-Escalation Study of the Safety and Anti-Inflammatory Activity of the p38 Mitogen-Activated Protein Kinase Inhibitor Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress Syndrome" @default.
• W2318121605 cites W1969889453 @default.
• W2318121605 cites W1979917404 @default.
• W2318121605 cites W1981747359 @default.
• W2318121605 cites W1987293334 @default.
• W2318121605 cites W1989565835 @default.
• W2318121605 cites W1991425488 @default.
• W2318121605 cites W1992598095 @default.
• W2318121605 cites W1994127425 @default.
• W2318121605 cites W1995620440 @default.
• W2318121605 cites W2014521622 @default.
• W2318121605 cites W2025756876 @default.
• W2318121605 cites W2031359438 @default.
• W2318121605 cites W2034441952 @default.
• W2318121605 cites W2038472314 @default.
• W2318121605 cites W2042905127 @default.
• W2318121605 cites W2044346605 @default.
• W2318121605 cites W2061628196 @default.
• W2318121605 cites W2070506007 @default.
• W2318121605 cites W2077554968 @default.
• W2318121605 cites W2077647582 @default.
• W2318121605 cites W2085863877 @default.
• W2318121605 cites W2089096428 @default.
• W2318121605 cites W2096379722 @default.
• W2318121605 cites W2100852364 @default.
• W2318121605 cites W2117678288 @default.
• W2318121605 cites W2124519382 @default.
• W2318121605 cites W2134998780 @default.
• W2318121605 cites W2138343036 @default.
• W2318121605 cites W2139937737 @default.
• W2318121605 cites W2144304154 @default.
• W2318121605 cites W2161328469 @default.
• W2318121605 cites W2163053457 @default.
• W2318121605 cites W2169079319 @default.
• W2318121605 cites W4294658238 @default.
• W2318121605 doi "https://doi.org/10.1097/ccm.0000000000001132" @default.
• W2318121605 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26102252" @default.
• W2318121605 hasPublicationYear "2015" @default.
• W2318121605 type Work @default.
• W2318121605 sameAs 2318121605 @default.
• W2318121605 citedByCount "29" @default.
• W2318121605 countsByYear W23181216052016 @default.
• W2318121605 countsByYear W23181216052017 @default.
• W2318121605 countsByYear W23181216052018 @default.
• W2318121605 countsByYear W23181216052019 @default.
• W2318121605 countsByYear W23181216052020 @default.
• W2318121605 countsByYear W23181216052021 @default.
• W2318121605 countsByYear W23181216052022 @default.
• W2318121605 countsByYear W23181216052023 @default.
• W2318121605 crossrefType "journal-article" @default.
• W2318121605 hasAuthorship W2318121605A5012242776 @default.
• W2318121605 hasAuthorship W2318121605A5012908451 @default.
• W2318121605 hasAuthorship W2318121605A5019832166 @default.
• W2318121605 hasAuthorship W2318121605A5029172499 @default.
• W2318121605 hasAuthorship W2318121605A5042741758 @default.
• W2318121605 hasAuthorship W2318121605A5046686843 @default.
• W2318121605 hasAuthorship W2318121605A5055992770 @default.
• W2318121605 hasAuthorship W2318121605A5064895812 @default.
• W2318121605 hasAuthorship W2318121605A5070182407 @default.
• W2318121605 hasAuthorship W2318121605A5074806717 @default.
• W2318121605 hasAuthorship W2318121605A5077430660 @default.
• W2318121605 hasAuthorship W2318121605A5085685364 @default.
• W2318121605 hasConcept C126322002 @default.
• W2318121605 hasConcept C142724271 @default.
• W2318121605 hasConcept C197934379 @default.
• W2318121605 hasConcept C204787440 @default.
• W2318121605 hasConcept C27081682 @default.
• W2318121605 hasConcept C2776348555 @default.
• W2318121605 hasConcept C2777714996 @default.
• W2318121605 hasConcept C2778375690 @default.
• W2318121605 hasConcept C2778384902 @default.
• W2318121605 hasConcept C2781090800 @default.
• W2318121605 hasConcept C71924100 @default.
• W2318121605 hasConceptScore W2318121605C126322002 @default.
• W2318121605 hasConceptScore W2318121605C142724271 @default.
• W2318121605 hasConceptScore W2318121605C197934379 @default.
• W2318121605 hasConceptScore W2318121605C204787440 @default.
• W2318121605 hasConceptScore W2318121605C27081682 @default.
• W2318121605 hasConceptScore W2318121605C2776348555 @default.
• W2318121605 hasConceptScore W2318121605C2777714996 @default.
• W2318121605 hasConceptScore W2318121605C2778375690 @default.
• W2318121605 hasConceptScore W2318121605C2778384902 @default.

• next